Edge Wealth Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Edge Wealth Management’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-500	Closed	-$2K	–	722
2020 Q1	$2K	Hold	500	–	–	﹤0.01%	560
2019 Q4	$5K	Hold	500	–	–	﹤0.01%	499
2019 Q3	$5K	Hold	500	–	–	﹤0.01%	486
2019 Q2	$8K	Hold	500	–	–	﹤0.01%	450
2019 Q1	$6K	Hold	500	–	–	﹤0.01%	456
2018 Q4	$5K	Hold	500	–	–	﹤0.01%	475
2018 Q3	$8K	Hold	500	–	–	﹤0.01%	466
2018 Q2	$8K	Hold	500	–	–	﹤0.01%	456
2018 Q1	$8K	Hold	500	–	–	﹤0.01%	418
2017 Q4	$7K	Hold	500	–	–	﹤0.01%	423
2017 Q3	$6K	Hold	500	–	–	﹤0.01%	433
2017 Q2	$5K	Hold	500	–	–	﹤0.01%	441
2017 Q1	$4K	Buy	+500	New	+$4.56K	﹤0.01%	430
2016 Q4	–	Sell	-2,000	Closed	-$22K	–	536
2016 Q3	$22K	Buy	+2,000	New	+$16.3K	0.01%	265
2015 Q3	–	Sell	-500	Closed	-$6K	–	486
2015 Q2	$6K	Sell	500 -1,500	-75%	-$20.8K	﹤0.01%	339
2015 Q1	$29K	Buy	+2,000	New	+$30.6K	0.01%	228

Edge Wealth Management's STML Position: Q2 2020 in Review

Edge Wealth Management sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 500 shares — an estimated $2K sold.

Edge Wealth Management first reported a position in STML in Q1 2015 and held it in 16 quarters. The position peaked at $29K in Q1 2015. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.

Edge Wealth Management reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
Edge Wealth Management sold 500 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $2K.
Edge Wealth Management first reported a position in Stemline Therapeutics, Inc. in Q1 2015 and held it in 16 quarters.
Edge Wealth Management's Stemline Therapeutics, Inc. position peaked at $29K in Q1 2015.
0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.

Based on Edge Wealth Management's 13F filing for Q2 2020, filed 3 Aug 2020.